Eversept Partners’s Exagen XGN Stock Holding History

Eversept Partners’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-104,437	Closed	-$1.83M	–	106
2021 Q1	$1.83M	Buy	104,437 +22,834	+28%	+$407K	0.14%	64
2020 Q4	$1.08M	Buy	+81,603	New	+$1.15M	0.13%	50

Other funds holding XGN

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Eversept Partners's XGN Position: Q2 2021 in Review

Eversept Partners sold out of Exagen (XGN) in Q2 2021, closing a stake of 104,437 shares — an estimated $1.83M sold.

Eversept Partners first reported a position in XGN in Q4 2020 and held it in 2 quarters. The position peaked at $1.83M in Q1 2021. 54 funds tracked by Wall St. Rank hold XGN as of Q2 2021.

Eversept Partners reported no remaining Exagen position as of Q2 2021 after selling out during the quarter.
Eversept Partners sold 104,437 Exagen shares in Q2 2021, an estimated $1.83M.
Eversept Partners first reported a position in Exagen in Q4 2020 and held it in 2 quarters.
Eversept Partners's Exagen position peaked at $1.83M in Q1 2021.
54 funds tracked by Wall St. Rank held Exagen as of Q2 2021.

Based on Eversept Partners's 13F filing for Q2 2021, filed 16 Aug 2021.